ASN-002 is an immunotherapy based on a virus engineered to destroy cancer cells when injected directly into the cancer. The product is based on a genetically modified form of human adenovirus type 5 – one of the viruses responsible for the common cold in humans. In ASN-002 the virus has been engineered to express the cytokine interferon-gamma (IFN-γ) which is a protein with powerful anti-cancer and immune promoting properties. When injected into the tumour, the adenovirus infection produces interferon-γ and interferon-α (as a response to the viral infection) locally resulting in an immune response against the cancer in addition to shutting off the blood supply into the cancer and causing the cancer cells to enter a process of programmed self destruction termed apoptosis. ASN-002 has been modified to be safe as the virus will not replicate after entering the cancer cells.
Ascend will focus the initial development of ASN-002 on nodular basal cell carcinoma, the most common form of skin cancer worldwide.
Evaluation of the density of tumour blood vessels in B16F0 tumours that were either untreated or treated i.t. with Ad-IFN-γ. Mice from the untreated group were sacrificed 10 days after tumour cell injections which correspond to the day of i .t. injections with Ad-IFN-γ*. The latter group of mice was sacrificed 17 days after adenovirus injections.
A). Immune infiltrates in a CTCL complete responder before and after ASN-002 treatment. Patient #24 at baseline (left panels) and at last visit, 4 weeks after last ASN-002 injection (right panels).
B). Immune infiltrates in a CBCL complete responder before and after ASN-002 injections. Patient #33 at baseline (left panels) and at ( D16, right panels)
For more details please download the ASE ASN-002 Overview For more details on current clinical trials : Current Clinical Trials